Monday 30 December 2024
Internal Reference Number: FOI_6786
Date Request Received: 20/09/2022 00:00:00
Date Request Replied To: 05/10/2022 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in Dermatology
Request Category: Researcher
| Question Number 1: How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs: • Abatacept • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Bimekizumab • Brodalumab • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Golimumab • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Tildrakizumab • Tofacitinib • Ustekinumab • Upadacitinib | |
| Answer To Question 1: Abatacept 0 Adalimumab Humira 6 Adalimumab biosimilar 19 Apremilast 8 BImekizumab 0 Brodalumab 10 Certolizumab <5 Dimethyl Fumarate 0 Etanercept Enbrel 0 Etanercetp biosimilar 0 Golimumab 0 Guselkumab 13 Infliximab Remicade 0 Infliximab biosimilar 0 Ixekizumab <5 Risankizumab 0 Secukinumab 6 Tildrakizumab 5 Tofacitinib <5 Ustekinumab 17 Upadacitinib 0 | |
| Question Number 2: How many patients were treated in the last 3 months by the Dermatology department for Psoriatic Arthritis (PsA) ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Apremilast • Certolizumab • Dimethyl fumarate • Etanercept - Enbrel • Etanercept Biosimilar • Guselkumab • Infliximab - Remicade • Infliximab Biosimilar • Ixekizumab • Risankizumab • Secukinumab • Ustekinumab | |
| Answer To Question 2: The Dermatology dept at SFT does not treat Psoriatic Arthritis (PsA). | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
